» Articles » PMID: 26003436

The Telehealth Enhancement of Adherence to Medication (TEAM) in Pediatric IBD Trial: Design and Methodology

Abstract

Medication nonadherence is a significant health care issue requiring regular behavioral treatment. Lack of sufficient health care resources and patient/family time commitment for weekly treatment are primary barriers to receiving appropriate self-management support. We describe the methodology of the Telehealth Enhancement of Adherence to Medication (TEAM) trial for medication nonadherence in pediatric inflammatory bowel disease (IBD). For this trial, participants 11-18 years of age will be recruited from seven pediatric hospitals and will complete an initial 4-week run in to assess adherence to a daily medication. Those who take less than 90% of their prescribed medication will be randomized. A total of 194 patients with IBD will be randomized to either a telehealth behavioral treatment (TBT) arm or education only (EO) arm. All treatments will be delivered via telehealth video conferencing. The patients will be assessed at baseline, post-treatment, 3, 6, and 12 months. We anticipate that participants in the TBT arm will demonstrate a statistically significant improvement at post-treatment and 3-, 6-, and 12-month follow-up compared to participants in the EO arm for both medication adherence and secondary outcomes (i.e., disease severity, patient quality of life, and health care utilization). If efficacious, the TEAM intervention could be disseminated broadly and reduce health care access barriers so that the patients could receive much needed self-management intervention.

Citing Articles

Challenges in Diagnosis and Management of Unusual Cases of Eosinophilic Enteritis in Rural Health Settings: A Comprehensive Review.

Ghosh S, Hiwale K Cureus. 2024; 16(3):e55398.

PMID: 38562345 PMC: 10982834. DOI: 10.7759/cureus.55398.


Improving medication adherence monitoring and clinical outcomes through mHealth: A randomized controlled trial protocol in pediatric stem cell transplant.

Ralph J, Sezgin E, Stanek C, Landier W, Pai A, Gerhardt C PLoS One. 2023; 18(8):e0289987.

PMID: 37590237 PMC: 10434937. DOI: 10.1371/journal.pone.0289987.


Patient education interventions for the management of inflammatory bowel disease.

Gordon M, Sinopoulou V, Ibrahim U, Abdulshafea M, Bracewell K, Akobeng A Cochrane Database Syst Rev. 2023; 5:CD013854.

PMID: 37172140 PMC: 10162698. DOI: 10.1002/14651858.CD013854.pub2.


Remote care through telehealth for people with inflammatory bowel disease.

Gordon M, Sinopoulou V, Lakunina S, Gjuladin-Hellon T, Bracewell K, Akobeng A Cochrane Database Syst Rev. 2023; 5:CD014821.

PMID: 37140025 PMC: 10164701. DOI: 10.1002/14651858.CD014821.pub2.


Patient Experience and Satisfaction with an e-Health Care Management Application for Inflammatory Bowel Diseases.

Zand A, Nguyen A, Reynolds C, Khandadash A, Esrailian E, Hommes D Int J Environ Res Public Health. 2021; 18(22).

PMID: 34831502 PMC: 8619840. DOI: 10.3390/ijerph182211747.


References
1.
Hovinga C, Asato M, Manjunath R, Wheless J, Phelps S, Sheth R . Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: survey of patients with epilepsy and physicians. Epilepsy Behav. 2008; 13(2):316-22. DOI: 10.1016/j.yebeh.2008.03.009. View

2.
Hommel K, Davis C, Baldassano R . Medication adherence and quality of life in pediatric inflammatory bowel disease. J Pediatr Psychol. 2008; 33(8):867-74. PMC: 2493513. DOI: 10.1093/jpepsy/jsn022. View

3.
Hommel K, Davis C, Baldassano R . Objective versus subjective assessment of oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008; 15(4):589-93. PMC: 2663377. DOI: 10.1002/ibd.20798. View

4.
Greenley R, Stephens M, Doughty A, Raboin T, Kugathasan S . Barriers to adherence among adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2009; 16(1):36-41. DOI: 10.1002/ibd.20988. View

5.
Ingerski L, Baldassano R, Denson L, Hommel K . Barriers to oral medication adherence for adolescents with inflammatory bowel disease. J Pediatr Psychol. 2009; 35(6):683-91. PMC: 2902844. DOI: 10.1093/jpepsy/jsp085. View